Found: 49
Select item for more details and to access through your institution.
Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study).
- Published in:
- Cancers, 2021, v. 13, n. 16, p. 4008, doi. 10.3390/cancers13164008
- By:
- Publication type:
- Article
Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Utility of the Absolute Lymphocyte Count and Neutrophil/Lymphocyte Ratio for Predicting Survival in Patients with Metastatic Breast Cancer on Eribulin: A Real-World Observational Study.
- Published in:
- Chemotherapy (0009-3157), 2019, v. 64, n. 5-6, p. 259, doi. 10.1159/000507043
- By:
- Publication type:
- Article
HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy.
- Published in:
- In Vivo, 2020, v. 34, n. 3, p. 1377, doi. 10.21873/invivo.11917
- By:
- Publication type:
- Article
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.
- Published in:
- Breast Cancer (13406868), 2020, v. 27, n. 4, p. 631, doi. 10.1007/s12282-020-01057-4
- By:
- Publication type:
- Article
Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.
- Published in:
- Breast Cancer (13406868), 2020, v. 27, n. 3, p. 389, doi. 10.1007/s12282-019-01029-3
- By:
- Publication type:
- Article
The efficacy and feasibility of dose-dense sequential chemotherapy for Japanese patients with breast cancer.
- Published in:
- Breast Cancer (13406868), 2018, v. 25, n. 6, p. 717, doi. 10.1007/s12282-018-0877-1
- By:
- Publication type:
- Article
Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).
- Published in:
- Breast Cancer (13406868), 2018, v. 25, n. 4, p. 438, doi. 10.1007/s12282-018-0843-y
- By:
- Publication type:
- Article
Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.
- Published in:
- Breast Cancer (13406868), 2018, v. 25, n. 1, p. 108, doi. 10.1007/s12282-017-0798-4
- By:
- Publication type:
- Article
Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.
- Published in:
- 2018
- By:
- Publication type:
- Erratum
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 173, n. 1, p. 123, doi. 10.1007/s10549-018-4964-y
- By:
- Publication type:
- Article
Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 171, n. 3, p. 675, doi. 10.1007/s10549-018-4873-0
- By:
- Publication type:
- Article
Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
- Published in:
- 2014
- By:
- Publication type:
- Report
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
- Published in:
- International Journal of Clinical Oncology, 2021, v. 26, n. 7, p. 1229, doi. 10.1007/s10147-021-01920-0
- By:
- Publication type:
- Article
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis.
- Published in:
- International Journal of Clinical Oncology, 2021, v. 26, n. 1, p. 1, doi. 10.1007/s10147-020-01818-3
- By:
- Publication type:
- Article
Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline-based Chemotherapy.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Risk factors of local recurrence following implant-based breast reconstruction in breast cancer patients.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Contribution of tumour and immune cells to PD‐L1 expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from KEYNOTE‐119.
- Published in:
- Journal of Pathology: Clinical Research, 2024, v. 10, n. 3, p. 1, doi. 10.1002/2056-4538.12371
- By:
- Publication type:
- Article
Correction: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
- Published in:
- Breast Cancer (13406868), 2024, v. 31, n. 3, p. 340, doi. 10.1007/s12282-024-01566-6
- By:
- Publication type:
- Article
The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2022 edition.
- Published in:
- Breast Cancer (13406868), 2024, v. 31, n. 2, p. 166, doi. 10.1007/s12282-023-01531-9
- By:
- Publication type:
- Article
Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.
- Published in:
- Breast Cancer (13406868), 2021, v. 28, n. 2, p. 335, doi. 10.1007/s12282-020-01162-4
- By:
- Publication type:
- Article
Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study.
- Published in:
- Breast Cancer (13406868), 2021, v. 28, n. 1, p. 145, doi. 10.1007/s12282-020-01138-4
- By:
- Publication type:
- Article
Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-00711-x
- By:
- Publication type:
- Article
Late resistance to adenoviral p53-mediated apoptosis caused by decreased expression of Coxsackie-adenovirus receptors in human lung cancer cells.
- Published in:
- Cancer Science, 2004, v. 95, n. 5, p. 459, doi. 10.1111/j.1349-7006.2004.tb03232.x
- By:
- Publication type:
- Article
Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).
- Published in:
- Breast Cancer Research & Treatment, 2023, v. 201, n. 3, p. 409, doi. 10.1007/s10549-023-07030-x
- By:
- Publication type:
- Article
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy.
- Published in:
- Breast Cancer Research & Treatment, 2023, v. 199, n. 2, p. 231, doi. 10.1007/s10549-023-06874-7
- By:
- Publication type:
- Article
A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17).
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 190, n. 3, p. 425, doi. 10.1007/s10549-021-06396-0
- By:
- Publication type:
- Article
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 188, n. 1, p. 117, doi. 10.1007/s10549-021-06184-w
- By:
- Publication type:
- Article
The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 185, n. 1, p. 125, doi. 10.1007/s10549-020-05921-x
- By:
- Publication type:
- Article
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 180, n. 3, p. 715, doi. 10.1007/s10549-020-05590-w
- By:
- Publication type:
- Article
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 180, n. 1, p. 135, doi. 10.1007/s10549-020-05524-6
- By:
- Publication type:
- Article
Fulvestrant with or without anti‐HER2 therapy in patients in a postmenopausal hormonal state and with ER‐positive HER2‐positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG‐C06).
- Published in:
- Cancer Medicine, 2023, v. 12, n. 17, p. 17718, doi. 10.1002/cam4.6390
- By:
- Publication type:
- Article
Differences in immune response to anesthetics used for day surgery versus hospitalization surgery for breast cancer patients.
- Published in:
- Clinical & Translational Medicine, 2017, v. 6, n. 1, p. 1, doi. 10.1186/s40169-017-0163-4
- By:
- Publication type:
- Article
Differences in immune response to anesthetics used for day surgery versus hospitalization surgery for breast cancer patients.
- Published in:
- Clinical & Translational Medicine, 2017, v. 6, n. 1, p. 1, doi. 10.1186/s40169-017-0163-4
- By:
- Publication type:
- Article
Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917).
- Published in:
- 2021
- By:
- Publication type:
- journal article
Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients.
- Published in:
- International Journal of Clinical Oncology, 2019, v. 24, n. 3, p. 274, doi. 10.1007/s10147-018-1353-9
- By:
- Publication type:
- Article
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients.
- Published in:
- International Journal of Clinical Oncology, 2015, v. 20, n. 4, p. 709, doi. 10.1007/s10147-015-0785-8
- By:
- Publication type:
- Article
Erratum to: Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients.
- Published in:
- 2015
- By:
- Publication type:
- Erratum
Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan.
- Published in:
- Breast Cancer: Basic & Clinical Research, 2019, v. 13, p. N.PAG, doi. 10.1177/1178223418825135
- By:
- Publication type:
- Article
Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study
- Published in:
- Breast Cancer: Basic & Clinical Research, 2018, n. 12, p. 1, doi. 10.1177/1178223418786243
- By:
- Publication type:
- Article
Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study.
- Published in:
- Japanese Journal of Clinical Oncology, 2023, v. 53, n. 3, p. 203, doi. 10.1093/jjco/hyac184
- By:
- Publication type:
- Article
Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.
- Published in:
- Japanese Journal of Clinical Oncology, 2022, v. 52, n. 6, p. 545, doi. 10.1093/jjco/hyac022
- By:
- Publication type:
- Article
Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.
- Published in:
- Japanese Journal of Clinical Oncology, 2020, v. 50, n. 1, p. 3, doi. 10.1093/jjco/hyz119
- By:
- Publication type:
- Article